We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.92B
AUM Growth
+$563M
Cap. Flow
+$657M
Cap. Flow %
13.36%
Top 10 Hldgs %
40.18%
Holding
111
New
29
Increased
28
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$126M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$95.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$76.9M
4
BIO icon
Bio-Rad Laboratories Class A
BIO
+$72.2M
5
PRTA icon
Prothena Corp
PRTA
+$62.2M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$186M
2
JNJ icon
Johnson & Johnson
JNJ
+$160M
3
MCK icon
McKesson
MCK
+$127M
4
UNH icon
UnitedHealth
UNH
+$124M
5
ABBV icon
AbbVie
ABBV
+$116M

Sector Composition

Rank Sector Weight
1 Healthcare 90.36%
2 Financials 0.49%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PNT
51
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$21.8M 0.44%
+2,820,000
New +$23.9M
PHAT icon
52
Phathom Pharmaceuticals
PHAT
$936M
$21.1M 0.43%
1,906,800
-13,000
-0.7% -$124K
COGT icon
53
Cogent Biosciences
COGT
$6.8B
$20.3M 0.41%
+1,357,700
New +$18.6M
NKTX icon
54
Nkarta
NKTX
$161M
$18.6M 0.38%
1,414,082
– –
ONC
55
BeOne Medicines Ltd
ONC
$34B
$17.8M 0.36%
+132,000
New +$22.7M
SIBN icon
56
SI-BONE Inc
SIBN
$797M
$17.4M 0.35%
996,700
-3,300
-0.3% -$52.8K
GOSS icon
57
Gossamer Bio
GOSS
$99.5M
$17.4M 0.35%
+1,450,000
New +$18M
CYTK icon
58
Cytokinetics
CYTK
$10.8B
$16.2M 0.33%
+335,000
New +$16.1M
ARQT icon
59
Arcutis Biotherapeutics
ARQT
$3.53B
$15.2M 0.31%
+794,500
New +$18M
PCVX icon
60
Vaxcyte
PCVX
$7.97B
$15.1M 0.31%
+628,700
New +$15.9M
ATEC icon
61
Alphatec Holdings
ATEC
$1.44B
$15M 0.3%
1,715,000
– –
KNTE
62
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$14.5M 0.29%
+1,212,611
New +$15.9M
IOVA icon
63
Iovance Biotherapeutics
IOVA
$2.11B
$13.2M 0.27%
1,382,900
-9,400
-0.7% -$108K
ANTX icon
64
AN2 Therapeutics
ANTX
$174M
$12.9M 0.26%
742,630
+54,300
+8% +$633K
IPSC icon
65
Century Therapeutics
IPSC
$363M
$12.9M 0.26%
1,303,600
+438,600
+51% +$4.62M
TMDX icon
66
Transmedics
TMDX
$2.59B
$12.5M 0.25%
+300,000
New +$13M
SGMO
67
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$11.6M 0.24%
+2,360,800
New +$12.1M
STOK icon
68
Stoke Therapeutics
STOK
$1.81B
$11.4M 0.23%
+891,100
New +$14.2M
SPNE
69
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$11.4M 0.23%
2,010,000
– –
NSTG
70
DELISTED
NanoString Technologies, Inc.
NSTG
$8.92M 0.18%
+698,200
New +$9.69M
ERAS icon
71
Erasca
ERAS
$6.28B
$7.66M 0.16%
982,500
-12,500
-1% -$101K
ALPN
72
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.19M 0.15%
998,600
+35
+0% +$288
SGRY icon
73
Surgery Partners
SGRY
$2.05B
$6.26M 0.13%
+267,600
New +$8.55M
SYRS
74
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.8M 0.12%
+900,000
New +$7.31M
CMAX
75
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$5.36M 0.11%
25,178
– –
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2022 Portfolio in Review

As of Q3 2022, Avidity Partners Management held 111 positions worth $4.92B, up 13% from $4.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $657M of net new capital in Q3 2022, opening 29 new positions and adding to 28 existing holdings. Its largest new stake was Sarepta Therapeutics: 948,200 shares worth $105M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was AstraZeneca, an estimated $186M trimmed.

  • Avidity Partners Management's largest Q3 2022 buy was Sarepta Therapeutics: 948,200 shares worth $105M.
  • Avidity Partners Management added most to Eli Lilly in Q3 2022, an estimated $126M increase.
  • Avidity Partners Management's biggest Q3 2022 reduction was AstraZeneca, cutting an estimated $186M.
  • Avidity Partners Management fully exited Johnson & Johnson in Q3 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.92B portfolio in Q3 2022.
  • Avidity Partners Management opened 29 new positions and closed 14 in Q3 2022.
  • Avidity Partners Management's portfolio value rose 13% quarter-over-quarter to $4.92B.

Based on Avidity Partners Management's 13F filing for Q3 2022, filed 14 Nov 2022.